A value-based reimbursement proposal from the Duke University Margolis Center for Health Policy that would incentivize drug companies to prioritize population-based payment contracts with payers was met with skepticism from insurers, government officials and even some sponsors.
Speaking at a Nov. 9 panel on economic incentives for developing antimicrobials, Gregory Daniel, deputy director of the Margolis Center,...







